Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of ST6GalNAc-II was significantly increased (P = 0.04) in cases with metastases to lymph nodes along the vascular trunk.
|
11389097 |
2001 |
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The SIATL1 gene, encoding STM, was mapped to the long arm of human chromosome 17 at q23-qter, a region that is nonrandomly deleted in human breast cancers.
|
11984005 |
2002 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, Southern analyses indicated that SIATL1 is usually not grossly rearranged in breast tumors.
|
11984005 |
2002 |
IGA Glomerulonephritis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Expression of ST6GALNAC2 in B peripheral lymphocytes was significantly lower in patients with IgAN than that in normal controls (3.7 +/- 2.2 versus 6.3 +/- 2.3, P = 0.016); alpha2,6-ST activity in B lymphocytes was correlated positively with the level of alpha2,6-sialic acid in serum IgA1 in patients (n = 42) and controls (n = 12) (r = 0.37, P = 0.007).
|
19170967 |
2009 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that potential genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity, and may contribute to the polygenic nature of IgAN.
|
19357720 |
2009 |
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide assessment of variability in human serum metabolism.
|
23281178 |
2013 |
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using this approach, we identified the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor.
|
24520024 |
2014 |
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.
|
24596201 |
2014 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study is to clarify the possible role and mechanism of ST6GalNAcII in the metastasis process of breast carcinoma.
|
24756995 |
2014 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In Gal-1-deficient mice, MCAM-silenced (MCAM(KD)) or ST6GalNAc2-overexpressing (ST6(O/E)) melanoma cells exhibited slower growth rates, underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth.
|
25756799 |
2015 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The present study investigated the alteration in expression of ST6GalNAcII involved in invasion and to clarify the possible mechanism of ST6GalNAcII in the metastasis process in human follicular thyroid carcinoma cell lines.
|
26820593 |
2016 |
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, taken together, our results imply that ST6GalNAcII activated the invasion in follicular thyroid cancer cells through regulating the activity of PI3K/Akt pathway.
|
26820593 |
2016 |